Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

Oncofertility counseling and fertility preservation in premenopausal women with early breast cancer

Dr Matteo Lambertini - University of Genova, Genova, Italy
Oncofertility counseling and fertility preservation in premenopausal women with early breast cancer ( Dr Matteo Lambertini - University of Genova, Genova, Italy )
18 Dec 2025

Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up

Dr Matteo Lambertini - University of Genova, Genova, Italy
Aromatase inhibitors improve disease-free survival in HR+/HER2+ early breast cancer: ALTTO 10-year follow-up ( Dr Matteo Lambertini - University of Genova, Genova, Italy )
18 Dec 2025

ESMO 2025: Latest developments in endometrial cancer

Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth
ESMO 2025: Latest developments in endometrial cancer ( Dr Shannon Westin, Dr Brian Slomovitz, Dr Vanda Salutari and Dr Christian Marth )
24 Oct 2025

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
23 Oct 2025

Best practice in precision medicine for prostate cancer

Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich
Best practice in precision medicine for prostate cancer ( Dr Elena Castro, Dr Pasquale Rescigno, Prof Gert Attard and Dr Axel Heidenreich )
21 Oct 2025

ESMO 2025: Prostate highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ESMO 2025: Prostate highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
20 Oct 2025

177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC

Dr Scott Tagawa - Weill Cornell Medicine, New York, USA
177Lu-PSMA-617 with androgen deprivation therapy plus ARPI improves PFS for mHSPC ( Dr Scott Tagawa - Weill Cornell Medicine, New York, USA )
20 Oct 2025

Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors

Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors ( Dr Javier C Cortés - Hospital Ruber Internacional, Madrid Spain )
20 Oct 2025

177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity

Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada
177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity ( Dr Kim Nguyen Chi - BC Cancer, British Columbia, Canada )
20 Oct 2025

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, USA
Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors ( Dr Erica Mayer - Dana-Farber Cancer Institute, Boston, USA )
18 Oct 2025

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC

Dr Mack Roach III - University of California San Francisco, San Francisco, USA
ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC ( Dr Mack Roach III - University of California San Francisco, San Francisco, USA )
7 Oct 2025